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background: Increased myocardial fibrosis (assessed by MRI) is associated with increased mortality and less symptomatic recovery after aortic 
valve replacement (AVR) in patients with aortic stenosis (AS). We hypothesized that circulating biomarkers of fibrosis may improve risk stratification 
of these patients.
methods: Subjects (n=342) with severe AS (AVA index ≤0.6 cm2/m2) referred for AVR were prospectively enrolled with blood specimens banked 
prior to AVR. Serum levels of ST2, Galectin-3 (Gal3), Pentraxin-3 (PTX3), and BNP were measured with commercially available assays. Mean follow-up 
was 14.5±11 months and 82 died. The associations between biomarker levels and all-cause death were evaluated by Kaplan Meier analysis and Cox 
PH models.
results: Patients had a mean age 80±10 years, indexed AVA 0.36±0.09 cm2/m2, STS score 7.6±5.6, 46% were female, and 78% underwent AVR 
(47% surgical, 53% transcatheter). In univariable analysis of continuous biomarker levels, increased ST2 (p<0.001), Gal3 (p=0.008), PTX3 (p=0.05), 
and BNP (p=0.008) were associated with increased mortality. After adjustment for performance of AVR and other clinical factors, ST2 ≥38 (41%) was 
associated with increased mortality (HR 1.89; 95% CI 1.06-3.38; p=0.03), but Gal3 and PTX3 were not. Among patients treated with AVR (n=266), 
ST2 ≥38 (40%) was associated with higher 1- and 2-yr mortality compared to ST2 <38 (1 yr: 25% vs. 10%, p=0.004; 2 yr: 32% vs. 14%, p=0.004). 
After adjustment for STS score, ST2 ≥38 was associated with increased mortality (HR 2.14; 95% CI 1.17-3.91; p=0.014), providing a continuous 
net reclassification index of 28% (95% CI 6-43%) at 1 yr and 34% (95% CI 4-50%) at 2 yrs. Gal3 and PTX3 did not reclassify patients, whereas BNP 
≥271 reclassified 22% (95% CI 4-40%) at 1 yr, but not at 2 yrs. The combination of ST2 ≥38 and BNP ≥271, adjusted for STS score, was associated 
with increased mortality (HR 3.46; 95% CI 1.4-8.3; p=0.005; referent: ST2 <38, BNP <271).
conclusion: In patients with severe AS referred for AVR, increased soluble ST2 (a biomarker of mechanical stretch, fibrosis, and inflammation) is 
independently associated with increased mortality, which may aid in risk stratification of these patients.
